Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
Times cited: 4
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses.
Journal of Hematology and Oncology.
Times cited: 75
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Journal of Clinical Oncology.
Times cited: 278